Aquestive Therapeutics Inc. Common Stock (NASDAQ: AQST)
20 Days left to seek lead plaintiff status.
The complaint alleges Defendants provided investors with material information pertaining to the timeline for approval and launch for Aquestive’s New Drug Application (NDA) for Anaphylm (Dibutepinephrine) sublingual film. Defendants’ statements included, among other things, confidence in the Company’s NDA submission and optimistic claims that Anaphylm would be approved by the Prescription Drug User Fee Act (PDUFA) date, January 31, 2026.